All In Biotech

Drug Trial Radar · NCT05343715

PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion

Comparative Pharmacokinetic and Pharmacodynamic Study Between 2 Agalsidase Beta Formulations at a Single Dose of 1 mg/kg of Agalsidase (Biosidus) and Fabrazyme (Sanofi Genzyme) as Intravenous Infusion in Male Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Oct 23, 2021

Primary completion

Mar 6, 2022

Study completion Apr 17, 2022

Sponsor

Lead sponsor
Bio Sidus SAIndustry
Sponsor type
Industry
First posted
Apr 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Pharmacokinetic/Pharmacodynamic Study of 2 agalsidase beta Formulations in Single Dose Administered to Healthy Volunteers as intravenous infusion, at a concentration of 1 mg/kg

Conditions

  • Fabry Disease

Interventions

  • Agalsidase beta from Biosidus 1 mg/kgBiological

    Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg

  • Fabrazyme (agalsidase beta) 1 mg/kgBiological

    Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Serum Concentration of Agalsidase Beta (Cmax)Time frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion
  2. Area Under the Curve of Serum Concentration Between Times 0 and 12 Hours of Agalsidase BetaTime frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion
  3. Time at Which Maximum Serum Concentration of Agalsidase Beta is Observed (Tmax)Time frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion
  4. Area Under the Curve of Serum Concentration, Resulting From the Extrapolation From Time 0 to Infinite TimeTime frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanatorio Nuestra Señora del Pilar

    Ciudadela, Buenos Aires, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.